Healthcare and Biotech SMEs: Modernising Under Compliance Pressure

Regulation is the reason most clinical and biotech SMEs put modernisation off. It is also, once you look properly, the reason they should not.

The argument for delay goes: our environment is regulated, changing systems creates validation work and risk, so we will do it when we have to. The argument against is that the current setup is usually generating compliance burden every single week in the form of manual checks, transcription and evidence-gathering that a better system would produce automatically.

This article is part of our guide to modernising a legacy business.

Where the burden actually sits

In most healthcare and biotech SMEs the same four things consume disproportionate time.

Evidence gathering. Producing the record that something was done correctly, after the fact, from systems that were not designed to produce it. Audit preparation that takes weeks is the symptom.

Transcription between systems. Results from an instrument into a spreadsheet into a report. Every hop is a transcription risk in an environment where transcription errors have consequences beyond the commercial.

Version control on documents. SOPs, protocols, validated methods. Where the controlled copy lives, who has the current one, whether the version someone used last month was the right one.

Training records. Who is trained on what, when it expires, and being able to demonstrate it. Frequently a spreadsheet, frequently out of date, and one of the first things an inspection looks at.

None of those are exotic technical problems. All of them are expensive.

The validation objection, honestly

The concern is legitimate: changing a system in a regulated environment creates qualification and validation work, and that work is real.

Three things are worth saying about it.

It applies to systems in the regulated path, not to everything. A great deal of what makes a clinical or biotech SME slow sits outside the validated boundary entirely: quoting, procurement, project tracking, document management for non-controlled documents, scheduling. Modernising those creates no validation burden and is routinely deferred anyway because the whole topic feels risky.

Incremental beats replacement, strongly, in this context. Wrapping a validated system so people do not have to touch it directly is often achievable without revalidating the system itself. Replacing it is not. See rip and replace vs modernise around the edges.

Deferring has a compounding cost. Systems that fall further out of support become harder and more expensive to validate a replacement for, not easier. The business that waits ten years faces a bigger project, not a smaller one.

Where AI fits, and where it does not

This sector attracts a particular quantity of AI marketing and deserves a plain answer.

Where it works now: summarising and searching internal documentation, drafting routine correspondence, extracting structured information from unstructured reports, triaging inbound queries, and making training and SOP material findable. All of these sit outside the clinical decision path and carry ordinary commercial risk.

Where it needs real care: anything touching a clinical decision, a diagnosis or a device function. Under UK rules, software that meets the definition of a medical device is regulated by the MHRA, and that definition catches more than people expect, including some clinical decision support. If you are building or deploying in that space, the regulatory position is the project, not a workstream within it.

Where it does not belong: anything where a confident wrong answer would reach a patient or a regulatory submission without a competent human in between.

The distinction to hold on to is the one between AI that helps a professional work faster and AI that makes a clinical judgement. The first is ordinary business software. The second is a regulated product.

What to do first

Training records and SOP version control. Outside the validated boundary in most organisations, universally painful, first thing an inspection asks for. This is the six-week win.

Then the transcription hops. Identify every point where a result or figure is retyped. Each one is both a cost and a risk, and removing them has a compliance argument as well as a commercial one, which is what gets it approved.

Then document search across your own material. Protocols, methods, past reports, regulatory correspondence. High value in an organisation where the answer usually exists and nobody can find it. See internal knowledge chatbots.

Then, and only with proper regulatory input, anything in the clinical path.

The data protection layer

Health data is special category data under UK GDPR and attracts significantly stricter requirements: a condition for processing in addition to a lawful basis, tighter security expectations, and a DPIA in most circumstances.

Practically, this means the question "where does this data go" has to be answered before any tool is adopted, not after. Public AI tools are generally not an acceptable destination for patient or participant data. Systems inside your own controlled environment are a different proposition.

This is also the sector where shadow AI carries the highest consequence, which makes staff training less optional than elsewhere.

Key Takeaways

• Deferring modernisation because the environment is regulated usually means paying a weekly compliance cost instead of a one-off project cost.
• Most of what makes a clinical or biotech SME slow sits outside the validated boundary and creates no validation burden to fix.
• Start with training records and SOP version control. Painful, unregulated, and the first thing an inspection asks for.
• Separate AI that helps a professional work faster from AI that makes a clinical judgement. The second is a regulated product, and the MHRA definition of a medical device catches more than people expect.
• Health data is special category data. Where it goes has to be settled before a tool is adopted, not after.

Frequently Asked Questions

Does using AI to draft a regulatory document create a problem?

Not inherently, provided a competent person reviews and takes responsibility for what is submitted, and provided the content does not leave your controlled environment inappropriately. The submission is yours regardless of how it was drafted. Treat it exactly as you would a draft from a junior colleague.

Our LIMS is twenty years old. Do we have to replace it?

Frequently not, and it is worth establishing why it is a problem first. If the complaint is that it cannot be queried, that people transcribe out of it, or that the interface is painful, those are solvable around it. If it is out of vendor support or cannot represent something you now do, that is a different conversation.

Can we use AI on patient or participant data?

Only within an appropriately controlled environment with the data protection position properly established, including the special category condition and a DPIA. Public consumer AI tools are not an appropriate destination for this data, and this is the single most important thing to train staff on.

Where does the MHRA line actually fall?

It is more nuanced than a blog article can settle, and the general shape is that software intended for a medical purpose, including diagnosis, prevention, monitoring or treatment, may be a medical device. Software that helps a clinician organise information generally is not. If your product is near that line, get regulatory advice before technical advice.

---

Running a healthcare or biotech SME and unsure what you can safely modernise? Talk to Halo Technology Lab. Our AI solutions for healthcare and biotech start outside the regulated boundary, where the return is quickest, and our work with Biosense took that route.